New drug cocktail takes on deadly brain cancer

NCT ID NCT06630260

Recruiting now Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial is testing two experimental drugs, avutometinib and defactinib, alone or with a standard chemotherapy (temozolomide), in people with high-grade malignant brain tumours like glioblastoma. The study aims to find a safe dose and see if the drugs can shrink tumours or stop them from growing. About 182 participants will be enrolled across multiple phases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: avutometinib and defactinib (with or without temozolomide)
What this could lead to: If successful, this could lead to a new treatment option for aggressive brain tumours like glioblastoma, potentially slowing disease progression.
What could go wrong: This is an early phase 1/2 trial with a small number of participants, so the drugs may not prove effective or safe enough for wider use. Side effects from the combination therapy are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 4 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 4 diffuse glioma, H3 G34 mutant glioblastoma glioma susceptibility 1 IDH-wildtype glioblastoma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT GLIOBLASTOMA MULTIFORM (GRADE IV ASTROCYTOMA) GLIOBLASTOMA MULTIFORME (GBM) MALIGNANT PRIMARY GLIOMAS

Contacts and locations

Locations

Cambridge University Hospitals
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
The Royal Marsden Hospital - Drug Development Unit
RECRUITING

Sutton, SM2 5PT, United Kingdom
The Royal Marsden Hospital - Neuro-Oncology Unit
RECRUITING

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.